• PN: B111188

COMPONENTS

45x Ab-conjugated beads

(S5P4 - human OPG Ab-bead). PN: B111188A. One vial containing 100 µL of anti-human OPG conjugated to AimPlex Bead S5P4.

25x Biotin-detection Ab (human OPG Biotin-dAb). PN: B111188B. One vial containing 100 µL of biotinylated anti-human OPG.

Lyophilized Standard Mix-Human Group 4 Panel A. PN: HG4009A. One vial containing lyophilized recombinant human BDNF, beta-NGF, EGF, FGF basic, OPG, OPN, PDGF-AB and VEGF-C.   Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human OPG.  Can be multiplexed with other analytes in Human Group 4.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 5 pg/mL

Quantitation range:

LLOQ: < 10 pg/mL

ULOQ: > 5,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Cross-reactivity of analytes in Human Group 4: Negligible

Sample volume: 15 µL/test

Description:

Osteoprotegerin (OPG), also known as osteoclastogenesis inhibitory factor (OCIF), or tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a cytokine receptor, and a member of the tumor necrosis factor (TNF) receptor superfamily. Osteoprotegerin is a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL). OPG can reduce the production of osteoclasts by inhibiting the differentiation of osteoclast precursors.  Elevated OPG levels has been reported in heart diseases in placebo effect serum responses in IBS patients and in severe mental disorders. Mutations in TNFRSF11B are associated with osteoarthritis. It has been found that osteoprotegerin is expressed on mesenchymal stem cells, which mediates their suppressive effect on osteoclastogenesis. It has been hypothesized that osteoprotegerin may be a link between bone and cardiovascular disease. It has been particularly related to the increase in cardiovascular risk in patients suffering from diabetes. Diseases associated with OPG/TNFRSF11B include Paget disease, juvenile and bone cancer.

References:

1.      Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (April 1997). "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density". Cell 89 (2): 309–19. doi:10.1016/S0092-8674(00)80209-3. PMID 9108485.

2.      Schoppet M, Preissner KT, Hofbauer LC (April 2002). "RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function". Arterioscler. Thromb. Vasc. Biol. 22 (4): 549–53. doi:10.1161/01.ATV.0000012303.37971.DA. PMID 11950689.

3.      Hope S, Melle I, Aukrust P, Agartz I, Lorentzen S, Steen NE, Djurovic S, Ueland T, Andreassen OA (September 2010). "Osteoprotegerin levels in patients with severe mental disorders". J Psychiatry Neurosci 35 (5): 304–10. doi:10.1503/jpn.090088. PMC 2928283. PMID 20569643.